These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 36652465)
1. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus. Lee K; Lee SK; Lee J; Jeon BK; Kim TH; Yu HT; Lee JM; Park JK; Baek YS; Kim DH; Shim J; Joung B; Lee MH; Pak HN; Park J PLoS One; 2023; 18(1):e0280359. PubMed ID: 36652465 [TBL] [Abstract][Full Text] [Related]
2. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Parkash R; Wells GA; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Sterns L; Bennett M; Roux JF; Rivard L; Leong-Sit P; Jensen-Urstad M; Jolly U; Philippon F; Sapp JL; Tang ASL Circulation; 2022 Jun; 145(23):1693-1704. PubMed ID: 35313733 [TBL] [Abstract][Full Text] [Related]
3. A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. Parkash R; Wells G; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Tang AS Am Heart J; 2021 Apr; 234():90-100. PubMed ID: 33472052 [TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure. Zhou L; Yang Y; Han W Ann Palliat Med; 2021 Oct; 10(10):10887-10895. PubMed ID: 34763450 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. Li CX; Liang S; Gao L; Liu H PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705 [TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238 [TBL] [Abstract][Full Text] [Related]
7. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Kirchhof P; Breithardt G; Camm AJ; Crijns HJ; Kuck KH; Vardas P; Wegscheider K Am Heart J; 2013 Sep; 166(3):442-8. PubMed ID: 24016492 [TBL] [Abstract][Full Text] [Related]
8. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes. Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953 [TBL] [Abstract][Full Text] [Related]
9. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Packer DL; Piccini JP; Monahan KH; Al-Khalidi HR; Silverstein AP; Noseworthy PA; Poole JE; Bahnson TD; Lee KL; Mark DB; Circulation; 2021 Apr; 143(14):1377-1390. PubMed ID: 33554614 [TBL] [Abstract][Full Text] [Related]
10. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial. Kuck KH; Merkely B; Zahn R; Arentz T; Seidl K; Schlüter M; Tilz RR; Piorkowski C; Gellér L; Kleemann T; Hindricks G Circ Arrhythm Electrophysiol; 2019 Dec; 12(12):e007731. PubMed ID: 31760819 [TBL] [Abstract][Full Text] [Related]
11. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. Jones DG; Haldar SK; Hussain W; Sharma R; Francis DP; Rahman-Haley SL; McDonagh TA; Underwood SR; Markides V; Wong T J Am Coll Cardiol; 2013 May; 61(18):1894-903. PubMed ID: 23500267 [TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality-of-Life Score: The CODE-AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry. Kim JY; Park HS; Park HW; Choi EK; Park JK; Kim JB; Kang KW; Shim J; Joung B; Park KM J Am Heart Assoc; 2022 Sep; 11(18):e025956. PubMed ID: 36073646 [TBL] [Abstract][Full Text] [Related]
13. Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation - the FIBRO-RISK study: Protocol for a non-randomized clinical trial. Korodi S; Toganel R; Benedek T; Hodas R; Chitu M; Ratiu M; Kovacs I; Mester A; Benedek I Medicine (Baltimore); 2019 Mar; 98(9):e14504. PubMed ID: 30817568 [TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236 [TBL] [Abstract][Full Text] [Related]
15. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis. Zhao Z; Jiang C; He L; Zheng S; Wang Y; Gao M; Lai Y; Zhang J; Li M; Dai W; Zuo S; Guo X; Li S; Jiang C; Liu N; Tang R; Long D; Du X; Sang C; Dong J; Ma C J Am Heart Assoc; 2023 Dec; 12(24):e031269. PubMed ID: 38084708 [TBL] [Abstract][Full Text] [Related]
16. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235 [TBL] [Abstract][Full Text] [Related]
17. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126 [TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study. Peng Z; Osmanaj F; Yang Y; Hua K; Yang X Europace; 2023 Nov; 25(11):. PubMed ID: 37939825 [TBL] [Abstract][Full Text] [Related]
19. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. Packer DL; Mark DB; Robb RA; Monahan KH; Bahnson TD; Poole JE; Noseworthy PA; Rosenberg YD; Jeffries N; Mitchell LB; Flaker GC; Pokushalov E; Romanov A; Bunch TJ; Noelker G; Ardashev A; Revishvili A; Wilber DJ; Cappato R; Kuck KH; Hindricks G; Davies DW; Kowey PR; Naccarelli GV; Reiffel JA; Piccini JP; Silverstein AP; Al-Khalidi HR; Lee KL; JAMA; 2019 Apr; 321(13):1261-1274. PubMed ID: 30874766 [TBL] [Abstract][Full Text] [Related]
20. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions. Fauchier L; Bisson A; Bodin A BMC Med; 2023 Feb; 21(1):54. PubMed ID: 36782248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]